Fungal positivity seen in tertiary care hospital during COVID-19 pandemic

Area of Science:

• Medical Mycology
• Infectious Diseases
• Critical Care Medicine

Background:

• The Coronavirus disease 2019 (COVID-19) pandemic has been linked to an increase in opportunistic invasive fungal infections, particularly in critically ill or immunocompromised patients.
• Fungal co-infections pose a significant clinical challenge, potentially worsening patient outcomes.

Purpose of the Study:

• To investigate the prevalence and types of fungal infections in patients during the COVID-19 pandemic.
• To analyze the fungal isolates from various clinical specimens in both COVID-19-positive and COVID-19-negative patients.

Main Methods:

• Retrospective analysis of clinical specimens from patients suspected of fungal infections.
• Fungal culture and identification from samples including urine, serum, respiratory secretions, nasal, and tissue samples.
• Comparison of fungal isolation rates between COVID-19-positive and COVID-19-negative patient groups.

Main Results:

• Fungal cultures were positive in 64% of COVID-19-positive patients versus 43% in COVID-19-negative patients.
• The most common fungi isolated from COVID-19 patients were Candida spp. (63%), Aspergillus spp. (15%), and Mucor spp. (6%).
• Candida species were frequently isolated from urine (27%) and respiratory samples (15%) in COVID-19-positive patients.

Conclusions:

• There was a notable increase in fungal co-isolations during the COVID-19 pandemic, highlighting a significant public health concern.
• The correlation between clinical symptoms and laboratory fungal isolation is crucial for timely diagnosis and effective management of these infections.
• Early detection and management of fungal infections in COVID-19 patients are essential to improve patient prognosis.